No Data
No Data
No Data
No Data
No Data
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss,
GlobeNewswireMay 1 08:30 ET
Express News | Veru Enrolls First Patients In Phase 2b Clinical Trial Of Enobosarm And Semaglutide Combination For Weight Loss
BenzingaApr 30 08:31 ET
Express News | Veru Inc: Topline Clinical Data Expected in Q4 Calendar Year 2024
ReutersApr 30 08:30 ET
Express News | Veru Enrolls First Patients in Phase 2B Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
ReutersApr 30 08:30 ET
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high qual
GlobeNewswireApr 25 08:30 ET
Express News | Veru Inc: On April 23, Received Notification Letter From Nasdaq Confirming That Co Regained Compliance
ReutersApr 25 07:17 ET
No Data
No Data